Alzheimer’s drug slows progression in patients. It may soon be approved in U.S. – National |…
Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If…